Putian E-commerce's Putean Medical Equipment Trading Platform Surpasses RMB 100 Million in Orders Within 10 Days of Launch
1. Putian Pharmaceutical and Medical Device Trading Platform Goes Live, Reaching Nearly 100 Million Yuan in Orders Within 10 Days
Recently, Putian Pharmaceutical and Medical Device Trading Platform, under the e-commerce arm of Putian, obtained the Class A qualification certificate for third-party drug transaction service platforms issued by the China Food and Drug Administration (CFDA). Within just 10 days of its approved launch, orders have approached RMB 100 million.
It is reported that Putian Pharmaceutical and Medical Device Trading Network secured orders worth hundreds of millions of yuan in a short period, thanks to its backing by the Boss Putian Health Industry Association. Notably, there are currently 8,600 Putian-affiliated hospitals across China, with annual pharmaceutical and medical device procurement volumes approaching RMB 100 billion. In the future, all such procurement is expected to be channeled through this online platform.
Drugs are delivered directly from manufacturers to hospitals, eliminating intermediaries. Conservatively estimated, this could reduce prices by 30%, thereby enhancing the competitiveness of private hospitals and benefiting patients.
2. Fitbit Announces Entry into Indian Market, Directly Targeting China’s Xiaomi Mi Band
On August 25, U.S. wearable health tracker brand Fitbit officially announced its entry into the Indian market. Its sports and sleep monitoring devices, including seven models of fitness bands, have gone on sale in India and are being distributed to more than 300 retail stores across the country. According to VCBeat, Fitbit’s goal is to become the leader in India’s smart band market, directly challenging China’s Xiaomi Mi Band, which currently holds a leading position in the Indian market.
According to The Economist, Fitbit plans to break into the top five in the Indian market within two years.
By the way, on the recent Inc. 5000 list, Fitbit led U.S. private digital health companies with $745 million in revenue.
3. Mobile Health Monitoring Device DynoSensor Secures $9.4 Million in Funding
On August 25 (U.S. time), DynoSense, a California-based company, raised $9.4 million in funding for its DynoSensor, a wearable sensor capable of monitoring a range of vital signs and other health metrics.
The company stated that DynoSensor can measure electrocardiogram (ECG), pneumoplethysmography (PPM), blood pressure variations, hydration levels, sleep, body temperature, and physical activity. Furthermore, it can capture 33 key health indicators from a single user activity within 60 seconds. After data collection, the device uploads the data to a cloud platform for analysis before transmitting it to healthcare teams. Users can access this data via mobile devices, set personalized alert thresholds, and share the information with family members and caregivers.
4. Pfizer Fined 100,000 for Illegally Paying “Display Fees”
According to the State Administration for Industry and Commerce website, Pfizer, the largest foreign-funded pharmaceutical company in China, recently had its illegal gains confiscated and was fined RMB 100,000 by the Shanghai Pudong New Area Market Supervision Administration for paying “display fees” to four pharmacies to prominently promote Viagra (a medication for treating erectile dysfunction).
Between 2011 and 2013, Pfizer entered into display agreements with Sinopharm Guoda Drugstore Shanghai Chain Co., Ltd., Shanghai Huashi Pharmacy Co., Ltd., Shanghai Fumei Yixing Pharmacy Chain Co., Ltd., and Shanghai Yanghetang Pharmaceutical Chain Management Co., Ltd., respectively. These agreements required the pharmacies to prioritize Pfizer’s products as key recommended items and ensure that its medicines had designated display locations.
To this end, Pfizer paid the aforementioned four pharmacies a total of RMB 926,180 in “display fees” over a two-year period. Subsequently, Pfizer derived illegal gains of RMB 2,956,834.56 from pharmaceutical sales.